Health Tech Innovator | Advancing digital health technologies 💡📚
Waterloo
Joined June 2022
- Tweets2K
- Following189
- Followers29
- Likes7.7K
Laura Morton retweeted
Adverse effects of immune-checkpoint inhibitors
Nature Reviews Clinical Oncology. 2019;16:563–580. DOI: 10.1038/s41571-019-0218-0.
Early recognition, prompt treatment and multidisciplinary management are essential to reducing severe toxicity and treatment-related deaths.
Laura Morton retweeted
Combination therapy ABBV-466 (RIZA+TROSU) seems to have added benefit in endoscopic healing at Wk12 and 24 with no additional infection risk
Presentation from @RPanaccione with some of exploratory mechanistic insights
#uegweek2026
Laura Morton retweeted
Postprostatectomy radiotherapy may be getting shorter - without sacrificing long-term cancer control.
Long-term NRG-GU003 data support 25-fraction hypofractionated RT as a potential alternative to the conventional 37-fraction course, with similar 5-year cancer control and patient-reported quality of life.
⚠️ The nuance matters: physician-reported grade 3 urinary toxicity was higher with the shorter schedule.
This is what meaningful de-escalation should look like:
same therapeutic goal, fewer hospital visits - but not at the expense of careful patient selection.
Would you consider 25 fractions your preferred postoperative schedule for an appropriate patient?
#ProstateCancer #RadiationOncology #Oncology #Radiotherapy #Hypofractionation #CancerCare #DeEscalation
Laura Morton retweeted
As Kenya’s Ebola situation evolves, Africa CDC supported the Ministry of Health and Kenya National Public Health Institute to engage editors and journalists on 14-15 October in Nairobi. A timely focus on accurate reporting and countering misinformation. #Africaready #AfricaHealthSecurity #Ebolaresponse
Laura Morton retweeted
🚨 #ESMO26 GU Oncology — Top picks by OncoAlert 🎯
#BladderCancer : VOLGA, KEYNOTE-B15, ENERGIZE, KEYNOTE-866
#ProstateCancer: DASL-HiCaP, CAPItello-281, PROTEUS
#KidneyCancer: LITESPARK-011 & -012, ivonescimab, PE-PE, SWOG S2200, XmAb819
Our Participating Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger , @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi , @AmandaNizamMD, @drenriquegrande, @nataliagandur
@AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun , @ravikanesvaran , @BraunMDPhD, @EfstathiouEleni, @mzugman , @crisbergerot, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @BRicciutiMD, @HHorinouchi, @UOzkerim, @p_ciracimd, @DrMirallas , @sonpavde , @Dr_Oncologista
Laura Morton retweeted
The Rise of Conversational AI in EMR Software
emrsystems.net/blog/the-rise…
#EMRSystems #Simplifyingselection #Healthcare #Digitalhealth #Healthtech #Doctors #Hospital #Health #Software #ConversationalAI #GenerativeAI #AIinHealthcare #HealthcareInnovation #MedicalTechnology
Laura Morton retweeted
Rebooting Cancer Care – Can AI Make Medicine More Human? - Adeena Musheer (@MusheerAdeena)
@dougflora2
oncodaily.com/voices/adeena-…
Laura Morton retweeted
DNA Methylation Profiling and AI in Precision Diagnostic Pathology - Wafik El-Deiry, MD, PhD, FACP
@weldeiry
oncodaily.com/science/wafik-…
Laura Morton retweeted
I’m asking about half-life, persistence and clearance studies- as comparing those loaded with cargo vs empty LNPs.
Laura Morton retweeted
📢 Join us at the 44th Annual Chemotherapy Foundation Symposium (CFS®): Innovative Cancer Therapy for Tomorrow**
📅 November 11–13, 2026
📍 New York, NY 🇺🇸
💻 Hybrid Meeting — In Person + Online
🎟️ FREE REGISTRATION with code: ONCOALERT
👉 buff.ly/b5A7hsf
For more than four decades, CFS® has brought together oncology professionals from around the world to explore the latest advances in cancer care.
This 3-day meeting will feature internationally renowned experts discussing practice-changing developments across **solid tumors and hematologic malignancies**, including:
🔹 Targeted therapies & immunotherapies\
🔹 Novel biomarkers and biomarker-driven treatment approaches\
🔹 Results from pivotal clinical trials\
🔹 Personalized treatment strategies based on evolving evidence\
🔹 Management of adverse events associated with novel therapies\
🔹 Emerging combination treatment strategies
🎓 Program Co-Chairs:
• Benjamin Levy, MD\
• John Mascarenhas, MD\
• Tiffany Traina, MD, FASCO
Don't miss this opportunity to connect with leaders in oncology, stay up to date on the latest evidence, and explore what’s next in cancer care.
🔗 **Register now:** buff.ly/b5A7hsf
@KCArbourMD @mishabeltran @KellyLBolton @HosseinBorghaei @AjaiChari @End\_myeloma @DrPinkalDesai @FordePatrick @MattGalsky @YJanjigianMD @DrHKantarjian @montypal @szusmani @HelenaYu923 @gotoPER
Laura Morton retweeted
The reason I keep bringing up these points is when you are licensed in BC you can do anything within your scope of practice immediately. But a group of administrators and Drs decided that doing a test requires 10 agencies to approve it, only in this province why? Why create an unnavigable system that doesn’t exist anywhere else
It nearly destroyed me trying to get patients access to EMG nerve testing. I went on the news; I tried to reach every level of the MOH. Endless emails sent me back to yet another 5th or 8th agency needed. In Ontario, you get your medical licence; you start testing. In BC, up to ten different approvals. Here, they tell you that the BC government agencies won't forward the documents or collaborate due to the PHYSICIANS' privacy??! So yes, there are more BC administrators to oversee testing than there are doctors who can do the tests. My colleague worked in Alberta; it was instant; they came to BC, and it was months of rejected forms and denials. Absolutley not one of these people knew the process of how to do it properly. They have a government framework to ENSURE THAT they do not work for the patients or physicians, only to serve their governance. The insanity e of BC governance leadership is that they create so many silos of agencies that no one knows how it actually works.
Laura Morton retweeted
$NWBO New material found:
Convenzis has published a 107-page collection of CancerCare 2026 conference slides. It contains an NHS presentation with useful new context for DCVax-L's potential UK implementation.
The most relevant material is Dr. Jessica Curtis's presentation on the NHS Cancer Vaccine Launch Pad (CVLP), pages 46-63.
What is significant?
The presentation provides concrete evidence of how extensively the NHS is developing infrastructure for personalized cancer immunotherapy trials.
Its reported progress includes:
-80 participating NHS locations and 26 trial locations.
-16 cellular pathology genomic centres.
More than 3,270 patients screened and 500 referred.
-More than 400 tissue samples prepared, with an average turnaround of 2.1 days.
Laura Morton retweeted
🗣️ "We’re hoping that by targeting mTOR1, we'll be able to overcome some of the mechanisms of resistance but still retain the safety signals that we want to see," Adanma Ayanambakkam, MD, MS, of @StephensonCC the background of the phase 1a FIT-001 trial of darlifarnib plus cabozantinib in RCC.
Full video ➡️: onclive.com/view/dr-ayanamba…
#kcsm #oncology
Laura Morton retweeted
The fascinating biological story of mitochondria...
"Scientists have mapped in unprecedented detail the proteins that make up the mitochondria in six organisms — five single-celled parasites and one plant — spanning the eukaryotic tree of life."
#Science #Biology #Evolution #Genetics
⏯️Unprecedented atlas explores mitochondria across the tree of life
nature.com/articles/d41586-0…
/
ALT Image Source: https://www.nature.com/articles/d41586-026-03195-9 The protein catalogue gives a dynamic picture of the mitochondria, beyond what was known from humans and yeast. Credit: Dr David Furness/Keele University/SPL
Laura Morton retweeted
🗞️ OncoAlert Newsletter | Oct 9–15
REGISTER here 👉 buff.ly/N5gYtAc
🕯️ Remembering Dr. Rachna Shroff: “If you can’t find the sunshine, be the sunshine.”
🚨 FDA approves adjuvant atezolizumab + chemo for Stage III dMMR colon cancer (ATOMIC: recurrence/death ↓50%)
📚 + NRG-BR002, KEYNOTE-966, LAURA
@Uromigos, @matteolambe, @aftimosp, @EdeAzambuja, @DrSGraff, @doublewhammied, @maryamlustberg, @raalbany, @hoperugo, @stolaney1, @LoiSher, @JaniceTNBCmets, @montypal, @DrDanielHeng, @apoloandrea, @DrChoueiri, @PGrivasMDPhD, @TiansterZhang, @neerajaiims, @amerseburger, @sonpavde, @drenriquegrande, @tompowles1, @cdanicas, @nataliagandur, @scocmem, @FernandoOnco, @ElisaAgostinett, @tobeelizabeth, @ErmanAkkus, @MarioBalsaMD, @DrMirallas, @GIMedOnc, @UOzkerim, @DrRishabhOnco, @PaulJiL, @DaisukeKotani, @DraMartinezLago, @pciracimd, @BenWestphalen, @CentralParkWMD, @graokane, @AmandaNizamMD
Laura Morton retweeted
Happening tomorrow: The Big Pink Youth Dialogue!
On 17 October, PMNCH supports a global conversation bringing young people and experts together to explore mental health, demographic change and women's health and well-being.
📅 9 AM ET | Online
🔗 us06web.zoom.us/meeting/regi…
Laura Morton retweeted
A cancer vaccine tailored to a patient’s tumor just hit its targets in a Phase 3 melanoma trial paired with Keytruda, after surgery. Promising? Yes. A universal cancer vaccine? Not yet.
🔗 Watch the full video: youtu.be/Z9BJb8lS1lo
Laura Morton retweeted
Choosing the right test for coronary artery disease depends on symptoms, clinical risk and patient factors.
From exercise ECG to stress imaging and coronary CT, each test has a different role in evaluating CAD.
@TrackYourHeart
#Cardiology #CoronaryArteryDisease #CardiacImaging #MedTwitter
Laura Morton retweeted
Given the decision not to foresee a role for PAs in Diagnostic Radiology, it would be helpful to understand what distinguishes IR and Clinical Oncology.
Shouldn't patient safety and the protection of doctors' training guide the approach consistently across all specialties?
